Cagrilintide: Long-Acting Amylin Analogue Pharmacology

Receptor pharmacology

Amylin receptors are heterodimers of the calcitonin receptor with receptor activity-modifying proteins RAMP1, RAMP2 or RAMP3, producing the AMY1, AMY2 and AMY3 subtypes. Cagrilintide is characterised as a non-selective agonist across amylin and calcitonin receptors, which distinguishes it from earlier selective amylin analogues.

The mechanistic point that matters when comparing it to incretin compounds is that amylin signalling and GLP-1 signalling reach satiety through independent pathways. That independence is the stated rationale for combination work rather than a marketing distinction.

The acylation strategy

Kruse et al. (J Med Chem, 2021) describe the development of cagrilintide directly. Native human amylin aggregates readily, which is what made it undevelopable as a therapeutic in its native form. The analogue addresses aggregation through sequence modification, and extends duration through lipidation that promotes reversible albumin binding.

This is the same half-life strategy used in semaglutide, and it is why both are once-weekly compounds. Reading the Kruse paper alongside the semaglutide design literature makes the shared engineering logic explicit.

Clinical literature

Lau et al. (Lancet, 2021) report the dose-finding phase 2 trial of once-weekly cagrilintide for weight management. Frias et al. (Lancet, 2023) report co-administration with semaglutide in type 2 diabetes.

Two 2025 New England Journal of Medicine papers, Garvey et al. and Davies et al., report coadministered cagrilintide and semaglutide in overweight or obese adults and in those with type 2 diabetes respectively. Buse et al. (Lancet Diabetes Endocrinol, 2026) report the REIMAGINE 2 phase 3 study comparing the combination against each component alone.

That last design is the useful one for separating mechanism: comparing the combination against both monotherapies is what distinguishes additive effect from simple dose escalation.